Chapters

Transcript

Video

Chimeric autoantigen-T cell receptor (CATCR)-T cell therapies to selectively target autoreactive B cells

Immunotherapies are often effective when treating autoimmune disease and cancer but often lead to impaired immune function. Rheumatologist Max Konig’s latest research uses newly engineered T-cell therapy helps to develop precision treatments for autoimmune disease and antiphospholipid syndrome.

Related Videos